Öberg & Sjöberg AB

An electromagnet unit for improving or promoting plant growth or development, the unit comprising:- a plurality of electric conductors, wherein the plurality of conductors extend, or are arranged, in a XY-plane, the plurality of conductors comprises, or is composed of, a first set of conductors and a second set of conductors, wherein the first set of conductors extend in parallel and are distributed, or spread out, in a first pattern in the XY-plane, and the second set of conductors are distributed, or spread out, in a second pattern in the XY-plane,- wherein the conductors of the first set are linear, or straight, and extend, or are arranged, in a first direction, or a Y-direction, of the XY-plane, and- wherein the conductors of the second set are composed of a first part that extends in the first direction, and a part that extends in a second direction, or X-direction,- wherein the second direction is transverse to, the first direction,wherein the first pattern is super positioned the second pattern, and together define, or form, combined pattern, in the XY-plane,- wherein the conductors are electrically insulated from one another in the combined pattern,- wherein the conductors are configured to be operationally coupled to an electric power source for generating a current in each of the conductors.

The technology proposed herein concerns a vaccine formulation comprising a) an antigen comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of the N-terminal region of a first group B Streptococcus surface protein, and b) a buffer having a pH of 6 to 8 and comprising: a. aluminum hydroxide gel particles, and b. a buffer system comprising: i. phosphate, and optionally also a salt, or ii. histidine, and optionally also a sugar. The technology proposed herein further concerns a method of producing a vaccine formulation as well as a vaccine formulation for use in a method of reducing, preventing and/or treating a GBS infection.

An immunogenic complex comprising i) an amino acid sequence of an N-terminal region of a group B Streptococcus surface protein selected from the group consisting of: a first amino acid sequence according to SEQ ID NO: 16, or an amino acid sequence having at least 98%, such as 99%, identity thereto; a second amino acid sequence according to SEQ ID NO: 18 or an amino acid sequence having at least 98%, such as 99%, identity thereto; and a third amino acid sequence according to SEQ ID NO: 20; and ii) a capsular polysaccharide, is provided. An immunogenic product, a vaccine, and the immunogenic complex, the immunogenic product or the vaccine for use in a method of preventing or treating a group B Streptococcus infection, are also provided.

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

A method of trapping particles, in a sample of a disperse liquid, having a non-zero acoustic contrast factor relative to a suspending liquid, comprising: i. providing an acoustofluidic device comprising a substrate in which a cavity is formed, the cavity being at least partially filled with a trapping matrix comprising or consisting of a material having a non-zero acoustic contrast factor, the cavity having an inlet for introducing the sample into the cavity, and an ultrasound transducer in acoustic contact with the substrate, ii. Introducing the sample into the cavity so the sample perfuses the trapping matrix, and iii. actuating the ultrasound transducer at an actuation frequency which does not correspond to a resonance of the cavity filled with the sample of disperse liquid, and couples an acoustic wave into the substrate. A system is also provided.